RhumbLine Advisers’s FibroBiologics FBLG Stock Holding History

RhumbLine Advisers’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,168	Closed	-$21K	–	4279
2025 Q1	$21K	Buy	1,168 +89	+8%	+$2.54K	﹤0.01%	3728
2024 Q4	$43.1K	Buy	1,079 +18	+2%	+$966	﹤0.01%	3681
2024 Q3	$65.6K	Sell	1,061 -92	-8%	-$6.12K	﹤0.01%	3633
2024 Q2	$115K	Buy	+1,153	New	+$220K	﹤0.01%	3475

Other funds holding FBLG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's FBLG Position: Q2 2025 in Review

RhumbLine Advisers sold out of FibroBiologics (FBLG) in Q2 2025, closing a stake of 1,168 shares — an estimated $21K sold.

RhumbLine Advisers first reported a position in FBLG in Q2 2024 and held it in 4 quarters. The position peaked at $115K in Q2 2024. 57 funds tracked by Wall St. Rank hold FBLG as of Q2 2025.

RhumbLine Advisers reported no remaining FibroBiologics position as of Q2 2025 after selling out during the quarter.
RhumbLine Advisers sold 1,168 FibroBiologics shares in Q2 2025, an estimated $21K.
RhumbLine Advisers first reported a position in FibroBiologics in Q2 2024 and held it in 4 quarters.
RhumbLine Advisers's FibroBiologics position peaked at $115K in Q2 2024.
57 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.